



CAPÍTULO REIVINDICATORIO MODIFICADO
(Segundo Examen de Fondo)

1. Un compuesto representado por la Fórmula estructural (II-A):



o una sal farmacéuticamente aceptable del mismo, en donde



R₂;

el enlazador L es un enlace;

R₁ es H;

cada instancia de R₂ es H, halógeno, CN, -OH, C₁₋₄ alquilo, C₁₋₄ haloalquilo, C₁₋₄ hidroxialquilo, -(CH₂)_nS(O)₂C₁₋₄ alquilo, -(CH₂)_nNR₇R₈, C₃₋₄ cicloalquilo, o heterociclilo de 3-6 miembros, en donde el heterociclilo representado por R₂ cada uno no está sustituido o está sustituido con uno o más grupos seleccionados entre halógeno;

cada instancia de R₃ es H, C₁₋₃ alquilo, o C₃₋₆ cicloalquilo, en donde dicho C₁₋₃ alquilo y C₃₋₆ cicloalquilo representado por R₃ cada uno no está sustituido o está sustituido con -OH;

cada instancia de R₄ es H, C₁₋₄ alquilo, C₂₋₄ alquenilo, ciclopentilo, tetrahydro-2H-piranilo, o 3,6-dihidro-2H-piranilo;

cada instancia de R₅ es H, F, CN, metoxi, o OCHF₂;

cada instancia de R₇ y R₈ es independientemente H, C₁₋₄ alquilo o ciclopropilo;

k es 0;

n es 0, 1 o 2; y



m es 0, 1, o 2.

2. El compuesto de la Reivindicación 1 o una sal farmacéuticamente aceptable del mismo, en donde





cada instancia de R₂ es H, halógeno, CN, C₁₋₃ alquilo, C₁₋₃ haloalquilo, C₁₋₃ hidroxialquilo, NH₂, N(CH₃)₂, NHciclopropilo, -(CH₂)_nS(O)₂C₁₋₃ alquilo, ciclopropilo,










azetidinilo, oxetanilo, morfolinilo, piperidinilo, tetrahidro-2H-piranilo, en donde dicho azetidinilo representado por R₂ no está sustituido o está sustituido con F; y
n es 0, 1, o 2.










3. El compuesto de la Reivindicación 1 o 2 o una sal farmacéuticamente aceptable del mismo, en donde
cada instancia de R₃ es H o C₁₋₃ alquilo;
cada instancia de R₄ es H o C₁₋₃ alquilo; y
cada instancia de R₅ es H, F, o OMe.











4. El compuesto de cualquiera de las Reivindicaciones 1-3 o una sal farmacéuticamente aceptable del mismo, en donde el anillo B es
- 
- , cada uno de los cuales no está sustituido o está sustituido con uno o dos grupos R₂.











5. El compuesto de cualquiera de las Reivindicaciones 1-4 o una sal farmacéuticamente aceptable del mismo, en donde cada instancia de R₂ es H, halógeno, CN, C₁₋₃ alquilo, C₁₋₃ haloalquilo, C₁₋₃ hidroxialquilo, NH₂, N(CH₃)₂, NHciclopropilo.
6. Un compuesto o una sal farmacéuticamente aceptable del mismo, en donde el compuesto es:










1	
16	
28	
156	









157	
162	
163	
170	
171	
176	
183	
184	
204	









205	
206	
30	
31	
35	
37	
38	
185	
192	









196	
197	
200	
201	
203	
207	
208	
209	
210	
211	









219	
220	
221	
227	
39	
40	
41	
234	
235	
236	









237	
61	
301	
302	
303	
267	
269	
270	
271	






272	
273	
274	
275	
276	
277	
279	
283	

284	
286	
289	
290	
308	
309	
63	
64	


77	
88	
91	
96	
99	
100	
104	
312	

313	
314	
315	
109	
117	
118	
119	
122	


123	
130	
134	
137	
59	
258	
259	
261	

262	
263	
264	
265	
266	


7. El compuesto de la Reivindicación 1, o una sal farmacéuticamente aceptable del mismo en donde el compuesto es




8. El compuesto de la Reivindicación 1, o una sal farmacéuticamente aceptable del mismo en donde el compuesto es




9. El compuesto de la Reivindicación 1, o una sal farmacéuticamente aceptable del mismo en donde el compuesto es




10. El compuesto de la Reivindicación 1, o una sal farmacéuticamente aceptable del mismo, en donde el compuesto es




11. El compuesto de la Reivindicación 6, o una sal farmacéuticamente aceptable del mismo en donde el compuesto es:




12. El compuesto de la Reivindicación 6, o una sal farmacéuticamente aceptable del mismo en donde el compuesto es:



13. El compuesto de la Reivindicación 6, o una sal farmacéuticamente aceptable del mismo en donde el compuesto es:



14. El compuesto de la Reivindicación 6, o una sal farmacéuticamente aceptable del mismo en donde el compuesto es:



15. Una composición farmacéutica que comprende una cantidad eficaz del compuesto de cualquiera de las Reivindicaciones 1 a 14 o una sal farmacéuticamente aceptable del mismo, y un vehículo farmacéuticamente aceptable.
